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Abstract 
Rationale Rodents exposed to valproic acid (VPA) in prenatal life exhibit post-natal 
characteristics analogous to autism spectrum disorder (ASD). Many previous studies 
used relatively high doses of VPA during early pregnancy, potentially confounding 
interpretation because the offspring are the „survivors‟ of a toxic insult. Low dose or 
late gestation exposure has not been widely studied. Objectives We examined the 
behavioral sequelae of late gestation exposure to low dose VPA in the mouse. We 
also examined postnatal levels of glutamic acid decarboxylase (GAD65 and GAD67) 
as markers for GABA neurons, because GABA pathology and subsequent 
excitatory/inhibitory imbalance is strongly implicated in ASD. Methods Pregnant 
C57BL/6N mice received a single subcutaneous injection of 100 or 200 mg/kg on 
gestation day 17. The control group received a saline injection on the same day. The 
offspring were tested in a battery of behavioral tests in adolescence and adulthood. 
Six brain regions were harvested and GAD65 and GAD67 were measured by western 
blotting. Results Compared to saline-exposed controls, adult mice exposed to prenatal 
VPA had impaired novel object exploration and fear conditioning anomalies. GAD67 
was decreased in midbrain, olfactory bulb, prefrontal cortex and increased in 
cerebellum, hippocampus and striatum; GAD65 was decreased in all 6 regions. 
Conclusions Our results suggest that a low dose of VPA in late pregnancy has 
persistent effects on brain development, and in particular the GABA system, which 
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may be relevant to ASD. Further attention to the impact of gestation time and dose of 
exposure in VPA-induced ASD models is encouraged.  
Keywords 
valproic acid; valproate; autism spectrum disorder; ASD; mouse; glutamic acid 
decarboxylase 
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1. Introduction 
Exposure to valproic acid (VPA) in pregnancy is associated with a higher incidence of 
autism spectrum disorder (ASD) by case reports and population studies [1-9]. Rodents 
exposed to VPA prenatally simulate a number of behavioural traits found in ASD [10, 
11]; eg. lower sensitivity to pain, increased repetitive/stereotypic-like activity, higher 
anxiety, decreased level of social interaction [12]. They have also been reported to 
recapitulate neurochemical and neuroanatomical features of ASD such as impaired 
inhibitory gamma amino butyric acid (GABA)-ergic synaptic transmission [13], 
increased frontal cortical serotonin [14], altered excitatory post-synaptic development 
[15]; and differences in brain structure and gene expression [16-19]. 
One of the challenges with this model is that it is difficult to translate the doses of 
VPA used in humans to the eqiuvalent in rodent. In humans, VPA is used within its 
relatively narrow therapeutic range, for example 20-30 mg/kg in epilepsy[20].  In 
contrast, rodents have been reported to be relatively resistant to VPA toxicity [21] and 
the majority of the reports that studies that link VPA exposure in pregnancy to 
ASD-like outcomes in rodents, have used either a moderate dose of VPA (200 mg/kg) 
over consecutive days, or a single high dose of VPA (500-800 mg/kg). However, 
these regimes can induce physical malformations and even death of offspring [11, 22, 
23]. Specifically, the usual rate of perinatal loss before the postnatal day 6 in rats is 
8.9%; but this increases to 15.6% following administration of 300 mg/kg VPA, and to 
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48.7% following administration of 500 mg/kg VPA[24]. This raises a question about 
how best to interpret results from survivors of such significant insults. Despite, this 
potential confound, few studies have examined low dose exposure to VPA in 
pregnancy in experimental settings [25-27].    
The gestational timepoint of exposure may also influence outcome following prenatal 
environmental exposures. For example, we and others have reported that exposure to 
maternal immune activation (MIA) in early or late gestation precipitates a distinct 
phenotype in terms of both nature and severity [28-30]. In the VPA model, the 
embryotoxicity of VPA initially came to light because it induced neural tube defects. 
As a result, many animal studies focused on the time of neural tube closure in early 
pregnancy [3, 31]. However, despite initial evidence that embryotoxicity following 
VPA exposure may be even higher in late gestation [32], the effects of late exposure 
VPA have received scant attention since.  
Finally, another over-looked factor which may influence the outcome of exposure to 
VPA in prenatal life, is the sex of the offspring. The majority of VPA studies have 
focused on male off-spring only, by convention and/or the reported higher incidence 
of males with ASD [33].  
Therefore, in this series of experiments we aimed to investigate the effects of low 
dose VPA (100 mg/kg or 200 mg/kg) administered to pregnant mice in the late 
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gestation. We examined juvenile and adult mice of both sexes in paradigms which 
measure behaviours relevant to ASD, namely open field activity, prepulse inhibition 
of startle (PPI) measure of sensorimotor gating, olfactory discrimination (adults only) 
and fear conditioning (adults only) paradigms. In addition, using western blot, we 
measured regional brain levels of Glutamic acid decarboxylase (GAD), the 
rate-limiting enzyme in the conversion of excitatory neurotransmitter glutamate to 
inhibitory GABA in the brain [34]. This is because brain excitatory/inhibitory 
imbalance is increasingly linked to ASD [35-38], and both GAD65 and GAD67 
isoforms, have been reported to be altered in ASD [39], and also in preclinical models 
of ASD such as the BTBR mouse [40] and the MIA model [41]. However, it is 
unknown whether prenatal VPA exposure alters GAD level postnatally.  
2. Materials and methods 
2.1 Animals and sample collections 
Twelve pregnant female C57BL/6N mice were supplied by HKU Laboratory Animal 
Unit (LAU) breeding colony - the day that a vaginal plug was identified was taken as 
embryonic day 0 (GD0). They were provided to the behavior unit within the LAU on 
GD15. The mice were maintained in a normal light cycle (lights on at 7:00; off at 
19:00) through-out the entire experiment. The temperature and humidity in the 
holding room was controlled at 21±1°C, and 55±5% respectively, and a conventional 
ad libitum food and water diet was supplied by the LAU. All experiments were 
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approved by the Committee on the Use of Live Animals in Teaching and Research at 
The University of Hong Kong, and every effort was made to minimize the number of 
animals used and their suffering. 
Valproic acid was purchased as sodium valproate (Sigma, St Louis, USA) and was 
dissolved in 0.9% saline to achieve a concentration of 20 mg/ml. Twelve pregnant 
mice were divided equally into 3 weight-matched groups and injected with 0.9% 
saline control (CON-0), 100 mg/kg VPA (VPA-100), or 200 mg/kg VPA (VPA-200) 
on GD17. Pregnant mice were housed individually and allowed to raise their own 
litters. Eighty mice were born in total. There were 13 female and 17 male in CON-0 
group, 14 female and 13 male in VPA-100 group, and 8 female and 15 male in 
VPA-200 group. Offspring were weaned on postnatal day 21 and mice of the same 
sex from the same litter were group housed in standard cages. No more than four 
animals were kept to a cage. All the mice were generally healthy and careful visual 
inspection revealed no abnormal physical features.  
The mice were weighed twice, once as juveniles in week 4 right after weaning and 
once in week 12 as adults. The open field test, the novel object recognition test and 
the prepulse inhibition (PPI) test were conducted at ages 5-6weeks and 12-15 weeks. 
Olfactory testing was conducted only in adulthood (week 16) because juvenile mice 
are known to respond unpredictably to odors [42]. The fear conditioning test was also 
only conducted once at the end of behavior tests (week 17), to avoid any residual 
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influence of the aversive nature of that test. MRI scan of mouse brain was conducted 
in 7 female and 7 male from each treatment group in week 19 (data under analysis and 
not reported here). After an undisturbed period all mice were sacrificed in week 22. 
Their brains were harvested and rapidly dissected to collect tissue samples from 
cerebellum (CB), hippocampus (HP), midbrain (MB), olfactory bulb (OB), prefrontal 
cortex (PFC) and striatum (STR).  
2.2 Behavioral tests 
2.2.1 Open field test  
The open field test was used to measure locomotor activity in the dim light and 
general anxiety levels in rodents in the bright light [43, 44]. The experimental setting 
comprised four identical square arenas (40 × 40 cm) surrounded on all sides by a 
40-cm white plastic wall. A central area (15 × 15 cm) was drawn in the center of each 
arena. A digital camera was mounted above, capturing images from all four arenas at 
the same time and the videos were analyzed by the EthoVision tracking system 
(Version 3.1, Noldus Information Technology). The mice were tested in squads of 
four. They were gently placed in the center of the appropriate arena in the dim light 
and allowed to explore undisturbed for 30-min. Locomotor activity was indexed by 
distance travelled recorded in successive 5-min bins and the anxiety-related behaviors 
were measured by distance travelled in the central area.  
 9 
2.2.2 Novel object Recognition test  
The procedure was adapted from previous protocols [45, 46]. A plastic cage  (30 × 
30 × 30 cm) with white walls was used in 3 sessions. In the habituation session on the 
first day, the mouse was placed into the empty cage to habituate for 10-min. On the 
second day, a 10-min training session preceded the 5-min test session by 1 hour. 
During the training session, two identical objects A (blue cylinder, 3 cm diameter × 1 
cm height,) were placed near the corners of one wall of the cage (5cm from each 
adjacent wall). The mouse was placed near the opposite wall, facing it, then allowed 
to explore both objects. During the test session, a fresh “familiar” object A‟ and a 
novel object B (pink cuboid, 3 × 1 × 1 cm,) were placed in the same place as objects 
in the training session and the mouse was allowed to explore. To avoid odor clues, the 
cage and objects were thoroughly cleaned with 70% ethanol between mice. The 
videos of the test phase were analyzed using the EthoVision tracking system and 
„Exploration‟ was defined as the nose of mouse placed within 1 cm of the object A 
(TA) and the object B (TB). A discrimination index (DI) was calculated as: DI = (TB 
− TA) / (TB + TA) × 100 
2.3.3 Prepulse inhibition (PPI) test 
The procedures and testing parameters for the PPI test used here followed those 
described previously [29]. Two standard acoustic startle chambers for mice (SR-LAB, 
San Diego Instruments, San Diego, CA, USA) generated the continuous background 
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noise of 65 dB and white noise stimuli. The white noise stimuli was set to be 100 dB, 
110 dB and 120 dB as three levels of pulse, and 71 dB, 77 dB and 83 dB as three 
levels of prepulse (+6 dB, +12 dB, +18 dB) over the background noise). The whole 
body response was transformed to an analogue signal by a piezoelectric unit then 
digitized and stored. PPI was calculated as the reduction of startle responses in the 
prepulse-plus-pulse trials relative to startle in pulse-alone trials. % PPI = (pulse-alone 
- prepulse-plus-pulse)/pulse-alone×100%.  
2.2.4 Olfactory test 
The protocol was adapted from that described previously [47]. The test apparatus was 
a rectangle box (30 × 30 × 30 cm) with a hanging holder in the center. The subject 
mouse was put into the box, with a dry cotton tip held in the holder. The animal was 
allowed to habituate to the setting for 2-min (Trial 0). The dry cotton tip was then 
exchanged for a series of tips soaked with different liquids. There were 15 continuous 
2-min trials as shown in Table 2.2. In trial 1-3 water was used to establish baseline 
activity. Trials 4-6 and 7-9, saturated solution of commercial milk tea powder and 
Commercial strawberry jam were used to investigate the responses to 2 non-social 
odors. In Trials 10-12 and 13-15, 2 mixed urine dilutions (1:100) were used as social 
odors. The urine mixes were collected each from 3 different mice held in a separate 
holding room. Urine from mice of the same sex as the subject mouse was always used. 
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The time and frequency that each mouse sniffed each cotton tip was recorded to index 
odor-attraction; the distance moved within each trial was also recorded.  
2.2.5 Fear-conditioning test 
The paradigm is based on the phenomenon that organisms can establish an association 
between a neutral environmental cue, the conditioned stimulus (CS), with an 
inescapable foot-shock, the unconditioned stimulus (US), when these two stimuli are 
closely paired. When conditioning is established, the CS alone can elicit fear [48]. 
The procedure was adapted from previous studies [49-51]. The apparatus comprised 
two identical conditioning chambers (25 × 25× 25 cm each). The front side was a 
fold-down door and the other three sides of the chambers were made from removable 
panels that slid onto rails. The wall panels were white color on one side and had 
patterns on the other side. The floor was composed of 4-mm steel rods placed 8.9-mm 
apart that connected to a computer-controlled „foot-shock‟ administrator. The 
chambers were entirely encased within a sound attenuating box with a door at the 
front. On the roof of the sound proofed box was a single white light bulb, an extractor 
fan, a black-and-white camera and a tone generator.  
The fear conditioning test was conducted over 3 days. Day 1 was the training session 
of 13.5-min. A mouse was placed into a conditioning chamber with the white side of 
wall panels facing inside. It was allowed to explore the chamber freely for 6-min 
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before 3 paired presentations of a clicker as the CS (30s, 4 Hz, 80 dB) and footshock 
as the US (2s, 0.5 mA) were presented. The inter-pair interval was 2-min with 2-min 
rest after the final clicker/shock pairing in the chamber. The chambers were cleaned 
with 70% ethanol between each training session. Day 2 was a context extinction test 
of 8-min. Each mouse was placed the same chamber used for training on Day 1 with 
no clicker and no foot shock. Their activity was measured. The floor was cleaned with 
70% alcohol between each subject. Day 3 was a cue test of 13.5-min. Each mouse was 
placed in a „novel‟ environment (the side wall panels were reversed so that the 
patterned surface faced inside and the grid floor was changed to a white flat panel). 
The first 6-min measured exploratory activity in novel context. And during the second 
6-min of the session, the clicker was played as in the training session, but without the 
foot shock. Between each session the floor was cleaned with Hibiscrub to remove 
olfactory cues from the alcohol used during training period.  
Freezing response (absence of movement except respiratory movement) was 
measured using the EthoVision tracking system and compared across groups in 5 
categories: pre-shock (the first 6-min of Day 1), associative learning (the last 7.5-min 
of Day 1 test,), context conditioning (8-min of Day 2 test), response to novel 
environment (the first 6-min of Day 3 test, to ensure there were no residual context 
cues available) and cue conditioning (the last 7.5-min of Day 3 test, response to CS 
alone). 
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2.3 Western blot for GAD65 and GAD67   
The brain tissues were homogenized at 4°C in lysis buffer (1:5, wt/vol) containing 1 
mM EDTA and 20 mM phenylmethylsulphonyl fluoride. The proteins from resultant 
supernatant were determined (Bio-Rad Protein Assay) for Sodium Dodecyl-sulphate 
Polyacrylamide gel electrophoresis (SDS-PAGE). Proteins (20 µg / lane) were 
subjected to electrophoresis on a 12% (wt/vol) polyacrylamide gel in SDS, and gels 
subsequently processed for electroblotting to polyvinylidene difluoride (PVDF) 
membranes. The blotted PVDF membranes were saturated with 5% (wt/vol) of 
skimmed milk in Tris Buffer Saline, pH 7.4 and 0.1% (vol/vol) of Tween 20 for 1 h at 
room temperature. The membranes were sequentially incubated with primary 
antibodies to the following proteins: GAD65 (rabbit polyclonal IgG antibody, 1:2000 
dilution, Abcam) or GAD67 (rabbit polyclonal IgG antibody, 1:2000 dilution, Abcam) 
for 1 h at room temperature. After thorough washing, the positive bands were 
revealed using ECL western blotting detection reagents and autoradiography film 
(Amersham, Biosciences, UK). The intensities of the bands were quantified using 
ImageJ software [52]. 
2.4 Statistics   
Data from the behavioral tests and western blot test were analyzed using a General 
Linear Model (GLM) in SPSS software with fixed factors Drug (saline, 100 mg/kg 
VPA, 200 mg/kg VPA) and Sex (female vs. male). For the tests that carried out twice 
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(weights, open field, novel object exploration and PPI), a repeated measures GLM 
included Age (juvenile vs. adulthood). Significant main effects of Drug were further 
explored using post-hoc Dunnett‟s test for the 3 levels of Drug. Significant 
interactions of Sex × Drug and/or Age × Drug were further explored by studying 
Drug effects in each sex and age subgroup. Chi-square test was used to compare the 
numbers of mice excluded from each group in the novel object recognition task. 
Pearson bivariate correlate analyses were used to investigate the relationship between 
cue and contextual conditioning in each group. Any difference in correlation 
coefficients was tested by conversion to z-scores 
(http://www.vassarstats.net/rdiff.html) [53]. To screen for potential outliers using a 
box plot approach, the relationship between cue and context conditioning was indexed 
as [%freezing cue conditioning - %freezing context]. A threshold of p < 0.05 (2-sided) 
was considered to be statistically significant. All data are presented as mean ± S.E.M. 
3. Results  
3.1 Physical features 
The number of offspring per litter and ratio of female to male was not different 
between the 3 groups (data not shown). VPA-100 mice and VPA-200 mice had no 
visible physical abnormalities. There was no significant main effect of Drug on the 
body weight. As expected males were heavier than females (Sex, F (1, 32) =35.511, p < 
0.05); adults were heavier than juveniles, (Age, F (1, 74) =867.251, p < 0.05). A 
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significant Sex×Drug interaction (F (2, 74) =4.266, p < 0.05) was explained because 
female VPA-treated mice, not males, were heavier than the corresponding controls (F 
(2, 32) =6.232, p < 0.05) in both the VPA-100 and VPA-200 dose conditions (Figure 1).   
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Figure 1. The body weight of the mice. 
The data are presented as means±S.E.M. *: Statistical significance (p < 0.05) 
 
3.2 Open field test  
There was no significant main effect of Drug or Sex. However, the effect of Age was 
significant - adult mice were more active than juveniles in all groups (Age, F (1, 74) 
=8.583, p < 0.05). There were no significant interactions with Drug on these 
measures.   
3.3 Novel object recognition test 
The mice that did not explore both objects (TB + TA =0) either as juvenile or as adult 
were excluded from the repeated measures analysis of DI. Although a greater 
proportion of VPA mice were excluded than controls, this was not statistically 
significant. There was no significant difference between the numbers excluded from 
each group (p >0.05) (Table 1). VPA treatment lowered DI as shown by a significant 
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main effect of Drug on DI (F (2, 45) =4.344,  p < 0.05). There were no main effects of 
Sex or Age, but significant Sex × Drug (F (2, 45) =6.109, p < 0.05) and Age × Drug (F 
(2, 45) =7.670, p < 0.05) interactions. Post-hoc testing confirmed that VPA lowered DI 
in both sexes in adulthood but not in juvenile males exposed to VPA-200 (Figure 2).  
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Table 1. The numbers of mice excluded from the DI calculation. 
  Tested Excluded  
CON-0 Female 13 4(30.8%) 
 Male 17 5(29.4%) 
VPA-100 Female 14 5(35.7%) 
 Male 13 3(23.1%) 
VPA-200 Female 8 5(62.5%) 
 Male 15 7(26.7%) 
 
Figure 2. The discrimination index (DI) of the mice in the novel abject 
recognition. 
The data are presented as means±S.E.M. *: Statistical significance (p <0.05) 
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3.4 Prepulse inhibition test  
Startle reactivity  
There was no significant main effect of Drug or Age on startle reactivity. Male mice 
had higher startle responses than females (F (1, 74) =13.979, p < 0.05) and louder Pulse 
caused greater startle (F (2, 148) =607.059, p < 0.05). There were no significant 
interactions with Drug.  
PPI 
There was no significant effect of Drug, Age or Prepulse on PPI. However, female 
mice had higher PPI than males (F (1, 74) =7.241, p < 0.05) and PPI was greater in 
louder Pulse conditions (F (1, 74) =7.241, p < 0.05). There were no statistically 
significant interactions with Drug.  
3.5 Olfactory test  
Sex dimorphism in the detection and/or processing of volatile urinary odors in mouse 
has been reported previously and, in particular, females are more sensitive to dilute 
urine samples [54]. Therefore, data from female and male mice in the olfactory test 
were analyzed separately. There was no significant difference between VPA-treated 
mice and the control mice of the same sex in total distance moved in this test, baseline 
activity (trial 1-3), response to non-social odors (trial 4-9) and response to social 
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odors (trial 10-15). The response to odors depended on the sequence that an odor was 
used; all three groups explored the cotton tips more when a new odor was presented, 
showing that they could distinguish the new odor from the former one (F (2, 1152) 
=46.681, p < 0.05).  
3.6 Fear conditioning test  
There was no significant main effect of Drug or Sex, and no significant interaction in 
measures of freezing during pre-shock, associative learning, context conditioning test, 
response to novel environment and cue conditioning test. All the 3 groups showed a 
higher level of freezing in the context test (F (1, 122) =447.511, p < 0.05) and the cue 
test (F (1, 145) =61.793, p < 0.05) relative to the pre-shock/pre-conditioning period, 
indicating that fear conditioning had taken place (Table 2). 
The relationship between context and cue conditioning was explored using Pearson 
correlations. In CON-0 mice, as expected, there was a significant negative 
relationship (r = -0.515, p = 0.020); that is, stronger cue conditioning was associated 
with weaker context conditioning and vice versa. But this did not exist in VPA-100 
mice (r = -0.027, p = 0.906), and was nearly (not reach the significance level) 
reversed in VPA-200 mice (r = 0.506, p = 0.093); that is, stronger cue conditioning 
was associated with stronger context conditioning (Figure 3A). One outlier in the 
VPA-100 group was identified. However excluding data from this animal did not 
materially alter the results (Figure 3B). Moreover, there was a significant difference 
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between correlation co-efficients in CON-0 mice and VPA-200 exposed groups (Z = 
–2.76, p < 0.05).  
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Table 2. The performance of mice in the fear conditioning test. 
The data are presented as mean±S.E.M.  
  Control    100 mg/kg    200 mg/kg  
 Total Female Male  Total Female Male  Total Female Male 
pre-shock 57.57±1.724 58.80±1.883 56.91±2.486  58.65±1.543 57.72±2.150 60.27±2.005  61.84±1.659 63.49±1.340 58.54±4.053 
context 89.42±1.254 89.06±2.927 89.61±1.230  89.51±1.633 87.45±2.317 93.11±1.282  89.69±1.687 89.86±2.130 89.34±3.173 
Cue 80.48±2.852 81.42±5.811 79.98±3.266  77.07±3.441 75.83±5.072 79.24±3.606  79.04±3.415 77.57±3.937 81.97±7.187 
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Figure 3. The relationship between context and cue conditioning. 
 
A. The relationship between context and cue conditioning of the three groups. In CON-0 mice, as expected, there was a significant negative 
relationship; That is, the more the animals learned that the explicit cue (the clicker) predicted a foot shock, the less they learned about the 
contextual stimuli (the panel setting of the box) to the foot shock. (shown by the solid line). But this did not exist in VPA-100 mice (shown by 
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the dotted line), and was nearly reversed in VPA-200 mice (shown by the dash line); that is, VPA-200 mice learn „indiscriminately‟ and form a 
relationship between the explicit or contextual cues to the foot shock equally. 
B. After deleting one outlier in the VPA-100 group that was identified in A, the results did not alter materially.  
 
 
 25 
3.7 GAD65 and GAD67 Western Blot analysis 
GAD65 in VPA-treated groups was significantly lower than the control group in all 
brain areas sampled: CB (F (2, 36) =9.046, p < 0.05), HP (F (2, 36) =26.873, p < 0.05), 
MB (F (2, 36) =4.700, p < 0.05), OB (F (2, 36) =4.186, p < 0.05), PFC (F (2, 36) =31.179, p 
< 0.05), STR (F (2, 36) =7.210, p < 0.05). The effect in the majority of regions was 
independent of Sex, with the exception of a significant Drug × Sex interaction in CB 
(F (2, 36) =8.816, p < 0.05) - VPA exposed males had lowest levels of GAD65; and in 
OB (F (2, 36) =3.613, p < 0.05) - VPA-exposed females had lowest levels of GAD65 
(Figure 4).  
GAD67 in VPA-treated groups was significantly lower than the control group in MB 
(F (2, 36) =41.445, p < 0.05), OB (F (2, 36) =13.492, p < 0.05) and PFC (F (2, 36) =13.267, 
p < 0.05), and was higher in CB (F (2, 36) =5.615, p < 0.05), HP (F (2, 36) =34.435, p <  
0.05) and STR (F (2, 36) =7.210, p < 0.05). Again in most regions this was independent 
of Sex; exceptions were a significant Drug × Sex interaction in MB and STR, where 
GAD67 differences were most prominent in male VPA-treated mice (Figure 4).  
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Figure 4. GAD65 and GAD67 in different brain areas  
 
*Statistically significance difference compared to control group post-hoc (p < 0.05).  
M
 Sex*Drug interaction - significant difference driven by male VPA mice.  
F
 Sex*Drug interaction - significant difference driven by female VPA mice.  
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4. Discussion 
The present study demonstrated that a single low dose of VPA in late gestation 
disrupted postnatal behavior and altered the levels of GAD65 and GAD67 in multiple 
brain regions of the offspring exposed. Mice exposed to low dose VPA in late 
embryonic life showed subtle but significant changes in stimulus processing 
underlying response to novelty or associative learning. The behavioral phenotype was 
partly influenced by sex and postnatal age of testing. However, compared to the saline 
control group, exposure to 200 mg/kg VPA did not invariably result in greater 
differences than 100 mg/kg VPA. The possibility that the VPA behavioral phenotype 
may be at least partly explained by a GABA system abnormality was signaled by 
abnormalities in regional GAD levels in VPA exposed groups. 
Behaviors altered by a low dose of VPA in late gestation  
Rodents exposed to VPA prenatally have been reported to simulate a number of traits 
found in ASD and this is consequently considered to be a promising animal model of 
aspects of the human condition[10, 11]. However, the dose regimes used (either a 
moderate dose over consecutive days, or a single high dose of VPA) may induce 
physical malformations and even death of offspring [11, 22, 23], and thus complicate 
the interpretation of the results generated from „survivors‟ of such a toxic insult. In 
addition, despite evidence that the timing of a gestational exposure may influence the 
outcome of offspring [26], this has been largely overlooked. Here, we found that mice 
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exposed to a low dose of VPA in late gestation did not cause embryonic death, or 
obvious congenital abnormalities, but did alter stimulus processing in both the novel 
object test and the fear conditioning paradigm, indicating that prenatal exposure to 
VPA causes persistent changes in response to the external environment. This is 
broadly in line with studies of sensory processing in ASD which report impaired 
sensory discrimination [55], as well as dysmodulation of sensory input and motor 
output [56, 57].  
Novel object recognition: The lower DI observed in VPA exposed animals could 
possibly be due to „memory‟ problems, that is, the VPA-treated mice did not 
„remember‟ the familiar objects and treated both objects in the test phase as novel. 
However, VPA exposed animals subsequently „remembered‟ the cue and contextual 
stimuli paired with a foot shock in the fear conditioning test, arguing against a general 
memory difficulty. Alternatively, the result could be explained by a „dislike‟ of 
novelty. The higher rate of exclusion of VPA animals due to non-exploration is 
consistent with this explanation, though this did not reach statistical significance. 
„Avoidance‟ is a feature of ASD. For example, as early as 1982, Kootz et al. noted 
that “rather than responding to novelty with orientation, observation, and exploration, 
the autistic child often responds with avoidance” [58]. Dislike of novelty is also 
reflected in an excessive adherence to routines or excessive resistance to change, one 
of the core symptoms of ASD [59].  
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Fear conditioning: In the fear-conditioning test there is learning about a „simple‟ or 
discrete cue (day 3), and learning about the contextual stimuli (day 2) [60]. This test 
revealed that VPA-exposed animals had clear differences from the control animals in 
the way they link explicit and contextual stimuli to a foot shock. In the control group, 
cue and contextual conditioning were negatively correlated. That is, the more the 
animals learn that the explicit cue (the clicker) predicts a foot shock, the less they will 
learn about the contextual stimuli (the panel setting of the box) to the foot shock. This 
pattern is predicted by animal learning theory, i.e. learning less about CS allows 
greater learning about context and vice versa [61]. This relationship did not exist in 
VPA-100 and was almost reversed in VPA-200 mice. Thus, VPA mice appeared to 
learn equally well about an explicit cue and contextual cues in the experimental set-up. 
Therefore, VPA animals appear to „indiscriminately‟ form a relationship between 
explicit or contextual cues and the foot shock. This may parallel the sometimes strong 
or unusual attachments or aversions to stimuli developed by a person with ASD; 
attachments which would not usually be formed by a person without ASD. 
Associative learning is governed by amygdala and hippocampal circuits [62]. In 
particular, the hippocampus is thought to regulate processing of contextual cues [63, 
64]. Thus „non-selective‟ associative learning by VPA exposed animals may be 
underpinned by some „disconnect‟ between amygdala and hippocampus hubs 
involved in stimulus processing. This potentially fits with reports that ASD-related 
difficulties in discriminating between conditioned and unconditioned fear stimuli stem 
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from “poor connectivity” between the amygdala and functional related cortical 
regions [65]; which is potentially due to a disruption in GABAergic signaling [66]. 
For example, a GAD65 knock-out has been reported to cause a generalization of cued 
fear (similar to that reported here) and impaired extinction of cued fear [66]; and our 
VPA exposed animals had significant reduction in GAD65 levels throughout the brain, 
including the hippocampus. Our results are also broadly consistent with observations 
by Markram and colleagues, who found that VPA-treated rats exhibited abnormally 
high and longer lasting fear memories [67]. However, since that team did not explore 
the relationship between CS and context conditioning, and we did not examine fear 
memories over a longer period, it is difficult to directly compare our 2 studies [67].  
Behaviors unchanged by a low dose of VPA in late gestation  
PPI: Low dose VPA exposure in late gestation did not disrupt preattentive stimulus 
filtering (PPI) or olfactory discrimination. Although PPI deficits have been reported in 
higher functioning adults with ASD [68] or Asperger‟s Disorder [69], equivocal PPI 
findings have been reported in lower functioning children and adolescents [70] and in 
a cohort of individuals with both high- and low functioning individuals with ASD 
[71]. A higher dose of VPA in late gestation has been reported to alter PPI [67], 
however other late gestation exposures which may increase risk of ASD - specifically 
maternal immune activation - do not disrupt PPI either [28-30]. Thus, a PPI 
impairment is not always a consequence of exposure to ASD risks. 
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Olfactory function: To date, there have been few studies examining olfactory 
function in ASD patients. In animal models of ASD, studies which include direct 
assessment of olfactory function suggest that social differences may explain olfactory 
abnormalities [72]. For example, newborn mice treated with prenatal VPA have intact 
basic olfactory function, but changes in odor-based behaviors [73].  
Thus, the absence of an effect of low dose VPA on PPI and olfactory processing does 
not negate prenatal exposure as of possible relevance to aspects of ASD.  
Changes in the GABA system 
GAD alteration in ASD: The behavioral alterations observed in our study were 
accompanied by widespread differences in GAD levels. Both isoforms of GAD, 
GAD67 and GAD65 are linked to ASD, but they are encoded by discrete, 
independently regulated genes (GAD1 and GAD2) and have distinct biochemical and 
cellular features [74]. GAD67 is present in readily detectable amounts in many 
GAD-containing cell bodies whereas GAD65 is particularly prominent in many axon 
terminals [75]. Here it appeared that prenatal VPA exposed had a „global‟ impact 
upon both isoforms of GAD. 
Differences in the expression of GAD isoforms have been reported in people with 
ASD: GAD65 and GAD67 has been reported to be lower in parietal and cerebellar 
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cortices [39]; GAD67 mRNA levels have been observed as lower in cerebellar 
Purkinje cells; GAD65 mRNA is lower in select subpopulations of neurons in the 
cerebellar dentate nuclei [76, 77]; and GAD67 mRNA expression is greater in 
cerebellar interneurons [78]. In the current study, animals exposed had lower GAD65 
in all 6 brain regions examined; GAD67 was lower in MB, OB and PFC, but 
increased in CB, HP and STR. Thus, the pattern of a general reduction in levels of 
both GAD isoforms, but greater GAD67 in the cerebellum, fits with the picture 
reported in the human condition [78]. Hence, disruption to the GABA system may be 
common to VPA exposure and ASD, and consistent with hypotheses that an 
excitatory/inhibitory (E/I) imbalance may therefore contribute to altered information 
processing in both the clinical condition and preclinical model [38, 79].  
Causes of GAD alteration in the VPA model: VPA may influence ASD risk in 
postnatal life via epigenetic mechanisms as it is a histone deacetylase inhibitor [80]. 
VPA-induced histone hyperactylation could have multiple consequences. For example, 
in cultured rat cortical neurons, VPA-treatment up-regulated 726 genes and 
down-regulated 577 genes, including GAD65 and 67 [81]. The epigenetic effects of 
VPA during embryo development are likely to be even more complex however, as 
histone acetylation depends upon both brain region and developmental stage [82]. 
Thus the effects of late gestation exposure to VPA on GAD65 and GAD67 may be 
quite distinct from an earlier insult, but more work is needed to examine this. 
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Methodological considerations 
VPA dose and gestation time of exposure: We chose a low dose of VPA compared 
to other studies of VPA model of ASD. In their first observations on the VPA mouse 
model of autism, Wagner et al [11] used 600mg/kg as a single s.c. injection on GD13, 
and 200mg/kg on six consecutive days. With this dose regime, only 9 out of 22 litters 
survived, compared to 8 out of 9 saline-treated litters. Consistent with this, in a recent 
report, an i.p. injection of 500mg/kg of VPA on GD9 induced obvious congenital 
malformations offspring at a rate of 30-40% [22]. In contrast, our results show that a 
single dose as low as 100mg/kg is sufficient to cause behavioural and biochemical 
abnormalities in offspring treated in utero with no overt effect on viability or 
malformation rate. A possible explanation for the impact of such a low dose VPA, 
may be VPA enrichment in especially in late gestation embryos. For example, after an 
s.c. injection of 550mg/kg VPA to pregnant mice, VPA concentration in embryo has 
been reported to be almost double of the concentration in the plasma of the dams [32]; 
and, for the same dose of VPA, the VPA concentration in embryos treated on GD7 is 
lower than in those treated on GD13 [32].  
Sex: The behavioral phenotype and level of GAD in VPA mice was minimally 
influenced by sex. Sexual dimorphism has been observed in many psychiatric 
disorders. Early-onset disorders (e.g., autism) show a marked male bias while 
adolescent-onset disorders (e.g., depression, anxiety) show a marked female 
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preponderance [83]. Early gestation exposure to VPA in the rat (600 mg/kg VPA on 
GD12.5) produced more severe symptoms in males, including lower sensitivity to 
pain, increased repetitive/ stereotypic-like activity, higher anxiety and decreased 
social interaction; whereas females had only increased repetitive/stereotypic-like 
activity [12]. However, consistent with our findings „fetal anticonvulsant syndrome 
associated ASD‟ is characterized by an even sex ratio [5].  
Limitations: We acknowledge that our study has a number of limitations. These 
include a modest sample size. This was in order to minimize the animal numbers used. 
However, to make the optimal use of this sample, a strength of our study was that we 
attempted to examine the developmental course of offspring by testing the same 
animals at both young adult timepoints. The disadvantage of this approach is that we 
cannot completely rule out the possibility that, for behavioral tests conducted twice, 
exposure to the first tests may affect the results of tests conducted later in life. In 
addition, we could only collect GAD measures ex-vivo in adulthood, therefore we 
cannot say for sure that the alterations in GAD observed are present from a young 
age.  
5. Conclusion 
The present study evaluated the postnatal effect of low dose VPA exposure during 
late prenatal life in mice. This regime induced some subtle behavioral abnormalities 
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and caused widespread changes to GAD levels compared to saline treated controls. 
Our results suggest that late gestation constitutes a period of vulnerability of the 
GABAergic system to environmental exposure in mice. Further work is needed to 
investigate if this observation translates to the human. 
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